J Liver Cancer Search


Instructions to authors

  • HOME
  • Instructions to authors

Aims and scope

Journal of Liver Cancer (J. Liver Cancer, JLC), an official journal of the Korean Liver Cancer Association (KLCA), is issued twice a year (March 31 and September 30) and published in English. The title of the journal is abbreviated to ‘J. Liver Cancer’. It was initially published by the name of The Journal of the Korean Liver Cancer Study Group as the formal scientific journal of the KLCA in 2002 (print ISSN 1596-6314), and has been renamed as JLC since its first edition in 2014.

The aim of the journal is to provide a forum for medical doctors and basic scientists working in the field of liver cancer. The journal covers basic and clinical researches on molecular and cell biology, pathophysiology, epidemiology, diagnosis, and treatment of the liver cancer, especially common in the East Asia including B viral related hepatocellular carcinoma. JLC publishes original articles, case reports, reviews, and articles in the field of liver cancer. All of the submitted papers are peer-reviewed and the decision would be informed to the readers within three weeks. Open access to full text article is available in the official website of JLC (http://www.e-jlc.org), KoreaMed, Google Scholar, KoMCI, and KCI. All articles published in the Journal will be immediately and permanently free for everyone to read and download. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Instruction for Authors

General information

Journal of Liver Cancer (JLC) is published and distributed by the Korean Liver Cancer Association. JLC is published online (www.e-jlc.org) and in print biannually in English. All authors who wish to submit to the JLC must comply with this instruction for authors and any instructions not described in this instruction for author will follow the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals” (http://www.icmje.org). All of authors should clearly indicate their position and institution (for example, Professor, Associate Professor, Assistant Professor, or Instructor). If a certain author is a medical student, student in high school, or minor research position, institution, and problems which the student belongs to should be reported.

Journal of Liver Cancer editorial office

Gangnam Finance Plaza 15-27, Teheran-ro, 419, Samsung-dong,
Gangnam-gu, Seoul
TEL: +82-2-313-1900, E-mail: liver@klcsg.or.kr

On-line Submission

All manuscripts should be submitted via our on-line manuscript submission service available at ‘http://www.e-jlc.org’.

Types of Manuscripts

The types of manuscripts are original articles (research papers), case reports, review articles (commentary papers), editorials, special contributions, and letters to editors. The editor commissions the review articles, editorials, and special contributions. According to the planning of the publication committee, the planning series report interesting cases of liver disease mainly in pathology or imaging findings.

Formatting Text

  • 1. Manuscripts should be prepared in English. The manuscript including the review article should be accompanied by an abstract in English. MS word (.doc or ..docx) may be used for manuscripts.
  • 2. Manuscripts should be written in 12-point basic fonts (Arial, Times New Roman), spaced by 3 cm between the left and right, top and bottom of A4 paper with double space between the sentences. Please mark the page at the bottom center from the text.
  • 3. Medical terminology applies to the glossary published by American Medical Association. Terms without proper translation, proper nouns, chemical names, units, etc. are used as they are. When the meaning of a translation is not clear, write the original word in the first parentheses and write only the translation afterwards.
  • 4. The name of the medicine has to use generic. When using the product name, the name, city and country of the manufacturer have to indicate in parentheses.
  • 5. Minimize the use of the English-abbreviation, and when it is repeated more than 2 times, spell out fully in the place where it was used first, and write the abbreviation in parentheses.
  • 6. The unit of laboratory inspection value is to use SI (International System of Units), but it is also possible to use non-SI unit values (Conventional Units). However, we must unify on one level.

Title page

This page should be written in English including the type of manuscript, the title of the manuscript; running title; the first and last names, and middle initials of all authors; the name and street address of the institution to which the authors belong; the telephone number, the fax or telex number, and the e-mail address of the corresponding author. The running title should be less than 40 characters in English. Title page should be submitted separately from the text of the document.


The abstract of an original article, should be written in English. Abstract of original articles must contain 250 words or less and must be organized as follows: Backgrounds/Aims, Methods, Results, and Conclusions. Five or less key words from MeSH terms (http://www.nlm.nih.gov/mesh/meshhome.html) should be provided at the end of the abstract. The abstract of the case report should be less than 150 words, the abstract of the review article and the special contribution should be written within 250 words and the contents of the manuscript should be summarized in one paragraph. When you use an abbreviation for the first time, spell out in fully in the abstract as well as in the text.

Main text

The text of original manuscripts should be arranged in sections under the following headings: Introduction, Methods, Results, and Discussion. Subheadings in the “Materials and Methods” and “Results” sections are encouraged. Avoid idiosyncratic word usage, nonstandard terms or abbreviations, and self-evaluation of your work (e.g., “novel,”, “unique”). For a randomized controlled trial, you can refer to the Consolidated Standards of Reporting Trials (CONSORT) report. For meta-analysis, you can refer to the PRISMA systematic review and meta-analysis.


Give only strictly pertinent background information and references that inform the reader as to why the study was performed. Do not review the literature extensively. The final paragraph should clearly state the hypothesis and purpose of the study in a fashion similar to the statement of purpose in the abstract. Brevity and focus are important.


Provide a level of detail such that another investigator could repeat the work. For methods that are used without significant modification, citation of the original work will suffice. Identify and provide references for all the statistical methods used. For studies using human subjects, the detail of IRB approval and patient informed consent, as well as related committee should address in paragraph. For animal experiments, provide a statement of approval by the institutional animal care committee or appropriate substitute.


Present the results in logical sequence in the text, along with tables and illustrations. Do not repeat data that are already covered in the tables and/or illustrations; summarize only important observations. Do not illustrate minor details if their message is adequately conveyed by simple descriptive text. Make sure to give results for all items evaluated as mentioned in Materials and Methods. State the statistical significance of the findings.


Emphasize the advances in knowledge provided by the study and the conclusions that follow from them. Do not repeat in detail the data given in the Results section. Include in the Discussion the implications of the findings and their limitations. Relate the observations to other relevant studies. Link the conclusions with the goals of the study, but avoid unqualified statements and conclusions not supported by the data. The penultimate paragraph of this section should address study limitations. For Experimental Studies articles, describe the importance of the conclusions as they relate to potential future practical applications.

Conflict of Interests

Identify financial supports and interests of authors related to the study.


An acknowledgement of persons who made a genuine assistance and provided special reagents may be included. Grant and financial support related with the work should be specifically stated.

Author Contributions

“Open Researcher and Contributor iD “(ORCID) iDs of the first author(s) and corresponding author(s) should be clearly indicated. What authors have done for the study should be described in this section. To qualify for authorship, authorship criteria is based on the International Committee of Medical Journal Editors (ICMJE) guidelines (Conception and design, acquisition of data, data analysis and interpretation, drafting the article, critical revision of the article, and final approval of the version to be published). Authors should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and it is expected that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time. (e.g., Study concept and design: OOO. Data acquisition: OOO. Data analysis and interpretation: OOO. Drafting of the manuscript; critical revision of the manuscript for important intellectual content: OOO. Statistical analysis: OOO. Obtained funding: OOO. Administrative, technical, or material support; study supervision: OOO).


The references must be written in English, in the order of citation, and should be numbered in the text. If the co-author is 6 or less, record all the authors’ name. If there are more than 7 co-authors, write the first 6 and then conclude “et al.” Journal names use recognized abbreviations.

1. Example of periodical journals:
Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, et al. Association between hepatitis B virus infection and the HLA-DR type in Korea. Hepatology 2000;31:1371-1373.

2. Example of a book:
Fraser RG, Pare JAP. Diagnosis of disease of the chest, 2nd ed. Philadelphia: Saunders, 1979:1420-1430.

3. Example of a chapter in a book:
Gumucio JJ, Berkowitz CM. Structural organization of the liver and function of the hepatic acinus. In: Kaplowitz N, ed. Liver and Biliary Diseases. Vol I. 2nd ed. Baltimore: Williams & Wilkins, 1992:2-17.

4. Example of abstract or article in a supplement:

  • A. Bellentani S, Marino M. Epidemiology and natural his¬tory of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009;8(Suppl 1):S4-S8.
  • B. Cho YJ, Lee SH, Kim BH, Yang SK, Jo YH, Lee DH. Characteristics of hepatocellular carcinoma with refer¬ence to ages in Korean patients [Abstract]. Hepatology 1998;28:246A.
  • C. Benhamou JP. Indications for liver transplantation in pri¬mary biliary cirrhosis. Hepatology 1994;20(Suppl):11-13.
  • 5. Website:
    National Cancer Information Center. Cancer incidence in Korea, 2010 [Internet]. Goyang (KR): National Cancer Information Center; [cited 2013 May 15]. Available from: http://ncc.re.kr/english/infor/kccr.jsp.


    Prepare tables on individual sheets of paper, double spaced and numbered consecutively with Arabic numerals in the order of their appearance in the text. The title of tables should be written concisely in clauses and phrases. The first letter of the table title starts with a capital letter. Explain all abbreviations and symbols such as *, †, ‡, §, Π, #, **, ††, ‡‡, §§, ΠΠ, ##. in alphabetical order at the bottom of the table. The statistical method used is specified in the footnote at the bottom of the table (e.g. * Mann-Whitney U-test). Do not duplicate the material presented in a figure.

    Figure legends

    Number the figures with Arabic numerals in the order they are mentioned in the text. The explanation is enough to understand the figure without looking at the text. When quoting the figure in the text, refer to “Figure 1”. For any copyrighted material, indicate that permission has been obtained. Figure legends should be typed consecutively on a separate sheet of paper.


    The figure should be sharp and resolution higher than 300 dpi is required. Resolution of more than 600 dpi is recommended for imaging medical photographs of black and white. As a general rule, the size of the figure should be at least 3 inches in width and smaller than 7 inches in size. For microscope photographs, the size should be 5 × 7 inches (12.5 × 18.0 cm). The file format is required as .jpg/.jpeg, .tif/.tiff, or ppt/pptx. In case of color photographs, the color or monochrome printing should be described in the photo description of the text file, and the expense shall be borne by the author.

    Guidelines for manuscript types

    Original articles

    Original manuscripts describing clinical and basic studies in the field of liver cancer. Manuscripts are expected to be wellorganized and clearly written. They should not exceed 6,000 words, including the abstract, references, tables, and figure legends. No more than 8 figures and tables, with a maximum of 6 panels per figure. It is permitted for you to submit additional methodological details, non-essential figures or portions of your manuscript as supplementary material for online publication only. References cited in the main text may not be listed in the supplementary materials. The only references be listed in the supplement are those cited exclusively in the supplement. References should not exceed a maximum of 40. Original article must arranged as follows: (1) title page (2) abstract (250 words or less with a list of 5 or less key words), (3) introduction, (4) materials and methods (or patients and methods), (5) results, (6) discussion, (7) acknowledgements, (8) conflict of interest statement (9) references, (10) tables, and (11) figure legends. Figure files can be uploaded for each file.

    Case reports

    A case report on rare form and clinical impact is posted. When a case report is submitted, it is first screened to determine whether it is appropriate. Only those cases that are new, and judged to have sufficient clinical impact, will go through peerreviewed procedures.

    • 1. Introduction: A brief introduction to the case report.
    • 2. Case report: 1. Clinical findings, 2. Image and pathologic findings, 3. Diagnosis and treatment progress. Clinical findings include a brief description of the patient’s sex, age, address (chief com- plaints), major medical findings, and laboratory findings. Image and pathologic findings are presented with a detailed description of the case. Diagnosis and treatment progress include the diagnosis of liver disease and liver cancer (Child-Pugh grade and TNM stage) and summarizes the important treatment progress.
    • 3. Discussion: The focus should be on the clinical significance associated with the characteristics of the case to be emphasized, avoiding redundant literature review. The abstract should be written in 150 words without paragraphs, 20 references, and 6 pictures.

    Review articles

    Review articles on selected topics of interest for the readers of the Journal of Liver Cancer will be solicited by the Editors. Review articles are expected to be clear, concise and updated. The maximum length is 5,000 words. The inclusion of a maximum of 8 high quality tables and/or colored figures to summarize critical points is highly desirable. Abstract should be written within 250 words without a paragraph.


    This section consists of invited brief editorial comments on articles published in the Journal of Liver Cancer. The length of an editorial should not exceed 1,500 words and 2 tables are allowed (usually no pictures). References should not exceed a maximum of 10.

    Special contribution

    A special contribution is a manuscript consisting of some original form of data about a single concern but not a complete scientific research study (original article). Abstract should be written in 250 words, 30 references, 8 pictures, 4 tables.

    Letters to the editor

    Letters to the editor consist of constructive criticism and questions about the papers listed in the Journal of Liver Cancer within previous two years. The authors submitting the letter should refer to the article to be discussed. The letters to be displayed should include the author contact information as appropriate. In order to hear the answer to this letter, the letter to the authors of the indicated article will be delivered. The authors of published papers will be able to know about the person who wrote the letter. Letters to the editor must arranged as follows: (1) title page, (2) body, and (3) references (maximum of 8) are allowed. Tables and figures are not included in these manuscripts. There are no word limits, but authors are encouraged to report within 2,500 words. Abstract is not required.

    Research and Publication Ethics

    • 1. The journal of liver cancer adheres to the ethical guidelines for research and publication described in International Standards for Editors and Authors of Committee on Publication Ethics (http://publicationethics.org/resources/internationalstandardsfor-editors-and-authors).
    • 2. For human research, the study should follow the Declaration of Helsinki (https://www.wma.net/what-we-do/medicalethics/declaration-of-helsinki). The researcher should explain to the subject or guardian the purpose of the study and the mental or physical risks that may occur during the study participation and be approved by the institutional review board (IRB). The name or initials of the patient should not be displayed and the patient’s identity should not be known when submitting photographs related to the patient. If there is a possibility that the patient’s identity may be exposed, it should be stated that the patient has given written consent.
    • 3. Animal studies should describe procedures that have been undertaken to reduce the pain and discomfort of laboratory animals and should state that the experimental procedure was not in conflict with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals or its equivalent. If necessary, submission of consent forms and approval of clinical trial ethics committees may be required.
    • 4. Any research that deals with a clinical trial should be registered with a primary national clinical trial registration site such as https://cris.nih.go.kr/cris/index.jsp, or other sites accredited by World Health Organization (WHO) or the International Committee of Medical Journal Editors.
    • 5. Any papers that are forged, altered, plagiarized, redundant, or dishonest cannot be published. All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the Editorial Board. The submitted manuscript will be checked for plagiarism using document similarity inspection service of Korea Citation Index (KCI, http://check.kci.go.kr).
    • 6. If a violation of the research ethics is found in the paper submitted to this journal, it is handled in accordance with the flowchart of the cheating recommended by COPE. The author of the paper and the institution, which the author belongs, will be notified of the violation and will receive the penalties determined by the research ethics committee.
    • 7. The corresponding author must inform the editor of any potential conflicts of interest that could influence the author interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.
    • 8. Authorship should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet these three conditions. There should be a list of each author’s role for the submitted paper. Please visit the website of the Korean Liver Cancer Association at ‘http://www.e-jlc.org/html/?pmode=sub’ to check Ethical Standards.

    Peer Review and Decision

    The Journal uses anonymous peer review in evaluating manuscripts for publication. The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Manuscripts are double-blind peer reviewed. Authors should be aware that manuscripts will be screened upon submission. As a rule, manuscripts are double-blind peer reviewed. Original manuscripts will be evaluated by two independent reviewers and by the Editors. Only the manuscripts which fully comply with the submission requirements outlined and in which the level of English is of an acceptable standard will enter the peer review process. The Editors reserve the right of early rejection without further external review if the manuscript is judged unlikely to be accepted. The Editors reserve the right to reject poorly written manuscripts even if their scientific content is qualitatively suitable for publication. Manuscripts requiring extensive revision will be at a disadvantage for publication and will be rejected. Authors shall be responsible for the quality of language and style and are strongly advised against submitting a manuscript which is not written in grammatically correct English. American or British English are equally acceptable as far as they are used consistently in the text.

    Resubmission of manuscripts

    In some cases, Authors will be invited to submit a revised version of the manuscript for further review. Revised manuscripts are double-blind peer reviewed. This invitation does not imply, in any case, that the revised version will be accepted for publication. In general, revised manuscripts must be received in the Editorial Office within three months of the date of the first decision. Authors should submit both a marked and unmarked version of the revised manuscript, with all changes in the marked copy underlined. The resubmitted manuscript should be accompanied by a cover letter stating that the manuscript has been revised according to the comments made by the Editor and the Reviewers. Figures and tables must be uploaded in the recommended formats. Revised manuscripts should be accompanied by a point-by-point reply to the critiques, specifying the changes made in the revised version, which should be highlighted. Please do not send revised manuscripts to the Editorial Office via e-mail.

    Submission Charge

    No charge for all kinds of manuscripts submitted to our online system.

    Copyright Tranfer

    Copyright for all material published in the Journal of Liver Cancer is vested in the Korean Liver Cancer Association. In accordance with the Copyright Act, all manuscripts must be accompanied by a Copyright transfer form signed by all authors and that follows these guidelines. Statements and opinions expressed in the articles and communications in the Journal of Liver Cancer are those of the author(s) and do not necessarily reflect the opinions of the Editor(s) or publisher, and the Editor(s) and publisher disclaim any responsibility or liability for such material. Neither the Editor(s) nor the publisher guarantees, warrants or endorses any product or service advertised in the journal; nor do they guarantee any claim made by the manufacturer of such product or service. Advertisements in publications are not authorized by the Korean Liver Cancer Association, so all legal liability lies with the advertiser.


    Moon Young Kim
    Gangnam Finance Plaza 15-27, 419 Teheran-ro, Samsung-dong, Gangnam-gu, Seoul, Korea
    Tel: +82-2-313-1900
    E-mail: liver@klcsg.or.kr

    • KoreaMed
    • KoMCI
    • GoogleScholar
    • Similarity Check
    • Crossref Cited-by Linking
    • CrossMark
    • Funder Registry
    • ORCID


    Browse all articles >

    Editorial Office
    1527 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
    Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

    Copyright © 2020 by The Korean Liver Cancer Association. All rights reserved.

    Developed in M2community

    Close layer
    prev next